MedXCell Science is a French Life science company active in the field of regenerative medicine. With the CHU of Montpellier as a shareholder and leveraging on its expertise, it is currently completing a clinical trial phase 2 (ADIPOA-2) for its allogeneic cell therapy treating mild to moderate knee osteoarthritis.
MedXCell Science results from the meeting between the University professor Christian Jorgensen (CHU Montpellier) and the entrepreneur Laurent Zbinden. The two founded MedXCell Science in 2018 together with the CHU of Montpellier, Prof. Noël and Prof. De Vos.
Help people enjoy a better, longer and healthier life
Develop and deliver innovative cell therapy treatments that improve people’s quality of life and mobility
We continuously strive to find disruptive and innovative solutions
Human respect and ethics - no dedicated tissue harvesting
We develop affordable therapies that make a real and positive difference to the greatest number of patients
We are committed in heart and mind to what we do